NEWARK, Calif., Nov. 4, 2020 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (NASDAQ: PTGX) today announced the acceptance of
one oral and four poster presentations at the American Society for
Hematology (ASH) annual meeting, taking place in a virtual format
December 5-8, 2020. The abstract data
includes results as of early August
2020 from the ongoing Phase 2 study of PTG-300 in the
treatment of polycythemia vera. Additional updated data from the
study will be available during presentations at the conference.
"This year's ASH meeting provides an opportunity for Protagonist
to share detailed findings of its PTG-300 hepcidin mimetic program
for polycythemia vera (PV) at a major medical conference for the
first time," commented Dinesh V.
Patel, Ph.D., Protagonist President and Chief Executive
Officer. "We look forward to presenting updated results from our
ongoing Phase 2 PTG-300 proof-of-concept PV study at the
conference. We will also present an analysis of real world patient
data and potential unmet need in PV, as well as promising
preclinical findings with a new oral hepcidin mimetic peptide. As a
non-cytoreductive treatment option based on the activity of a
natural hormone, PTG-300 has truly transformative potential for PV
patients and we look forward to advancing PTG-300 on the path
toward regulatory approval as efficiently as possible."
Oral presentation:
1)
Title: PTG-300 Eliminates the Need for Therapeutic Phlebotomy in
Both Low and High-Risk Polycythemia Vera Patients (Abstract
#482)
Session: 634. Myeloproliferative Syndromes: Clinical: Clinical
Trials in Polycythemia Vera
Session Date: Sunday, December 6,
2020
Presentation Time: 2:45 p.m. PST
Presenter: Marina Kremyanskaya,
M.D., Ph.D., Icahn School of Medicine at Mount Sinai
Poster presentations:
2)
Title: Hepcidin Mimetic (PTG-300) Reverses Iron Deficiency While
Controlling Hematocrit in Polycythemia Vera Patients (Abstract
#1689)
Session: 102. Regulation of Iron Metabolism: Poster II
Date: Sunday, December 6, 2020
Presenter: Yelena Ginzburg, M.D.,
Icahn School of Medicine at Mount Sinai
3)
Title: Real-World Treatments and Thrombotic Events in Polycythemia
Vera Patients: A Retrospective Analysis between 2018-2019 in US
Population (Abstract #2998)
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical
Studies: Poster III
Date: Monday, December 7, 2020
Presenter: Srdan Verstovsek, M.D., Ph.D., MD Anderson Cancer
Center
4)
Title: Mechanism of Systemic Iron Regulation and Hematocrit Control
by Hepcidin Peptidomimetics in Pre-Clinical Models (Abstract
#2594)
Session: 102. Regulation of Iron Metabolism: Poster III
Date: Monday, December 7, 2020
Presenter: Roopa Taranath, Ph.D.,
Protagonist Therapeutics
5)
Title: Hepcidin Peptidomimetics – Oral Efficacy in Pre-Clinical
Disease Model of Iron Overload (Abstract #2592)
Session: 102. Regulation of Iron Metabolism: Poster III
Date: Monday, December 7, 2020
Presenter: Roopa Taranath, Ph.D.,
Protagonist Therapeutics
Abstracts are available via the ASH meeting website at
https://www.hematology.org/meetings/annual-meeting.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based therapeutics to address significant
unmet medical needs and transform existing treatment paradigms for
patients. PTG-300 is an injectable hepcidin mimetic in development
for the treatment of polycythemia vera and other blood disorders.
PTG-200 is an orally delivered, gut-restricted, interleukin-23
receptor specific antagonist peptide in development for the
treatment of inflammatory bowel disease, with Crohn's disease as
the initial indication. In addition to PTG-200, two oral peptide
interleukin-23 receptor antagonist candidates from a collaboration
with Janssen Biotech, Inc., are in development and have been
selected for advancement into clinical studies. PN-943 is an orally
delivered, gut-restricted alpha-4-beta-7 integrin specific
antagonist peptide in development for the treatment of inflammatory
bowel disease, with ulcerative colitis as the initial targeted
indication.
Protagonist is headquartered in Newark, California. For further information,
please visit http://www.protagonist-inc.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements
include statements regarding our intentions or current expectations
concerning, among other things, the potential of our product
candidates to improve standards of care, our ability to fund
operations into future periods, and our expectations regarding the
timing of the initiation of clinical trials. In some cases,
you can identify these statements by forward-looking words such as
"anticipate," "believe," "may," "will," "expect," or the negative
or plural of these words or similar expressions. Forward-looking
statements are not guarantees of future performance and are subject
to risks and uncertainties that could cause actual results and
events to differ materially from those anticipated, including, but
not limited to, our ability to develop and commercialize our
product candidates, our ability to earn milestone payments under
our collaboration agreement with Janssen, the impact of the current
COVID-19 pandemic on our discovery and development efforts, our
ability to use and expand our programs to build a pipeline of
product candidates, our ability to obtain and maintain regulatory
approval of our product candidates, our ability to operate in a
competitive industry and compete successfully against competitors
that have greater resources than we do, and our ability to obtain
and adequately protect intellectual property rights for our product
candidates. Additional information concerning these and other
risk factors affecting our business can be found in our periodic
filings with the Securities and Exchange Commission, including
under the heading "Risk Factors" contained in our Quarterly Report
on Form 10-Q for the quarter ended September
30, 2020, filed with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and our actual results of operations, financial
condition and liquidity, and the development of the industry in
which we operate, may differ materially from the forward-looking
statements contained in this press release. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. We assume no obligation
to update our forward-looking statements, whether as a result of
new information, future events or otherwise, after the date of this
press release.
View original
content:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-present-updated-clinical-data-for-hepcidin-mimetic-ptg-300-in-polycythemia-vera-at-the-american-society-for-hematology-ash-2020-annual-meeting-301166424.html
SOURCE Protagonist Therapeutics, Inc.